Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » About Us » Our Staff » John Gilmore

John Gilmore

Staff Reporter
Phone Number
212-651-5628
Email
[email protected]

Articles Authored by John Gilmore

Jan 21, 2021

OncoLab Diagnostics Targets Cancer Recurrence Monitoring with CTC-Derived Biomarker Assay

Premium

The firm expects to receive a CE mark later this year for its RT-qPCR breast cancer recurrence assay, which characterizes epithelial CTCs by detecting cytokeratin-19 expression.

Dec 17, 2020

Stanford Team Develops Mathematical Model of ctDNA Shedding to Predict Lung Cancer Tumor Size

Premium

The method may improve the performance of circulating tumor DNA-based detection assays for routine screening and cancer relapse testing.  

Dec 10, 2020

Menarini's CellSearch Shows CTCs' Potential to Predict Breast Cancer Prognosis, Treatment Response

Premium

A meta-analysis showed that early circulating tumor cell dynamics were associated with overall survival using Menarini Silicon Biosystems' CellSearch assay.

Dec 07, 2020

Ceres Nanosciences Hydrogel Technology Shows Promise for Capturing Circulating Tumor DNA

Premium

Ceres plans to develop its Nanotrap technology to isolate undetectable levels of circulating tumor DNA in blood samples from non-small cell lung cancer patients.

Nov 20, 2020

Agena Bioscience Shows Off New Liquid Biopsy QC Assay at AMP; Expects January Launch

Premium

The firm also discussed recent studies comparing its UltraSeek lung cancer assay with more established liquid biopsy tests to detect drug-resistant mutations.

Nov 11, 2020

HTG to Expand Disease Reach With New Whole-Transcriptome Profiling Product Mid-2021

Premium

The firm aims to launch an early-access program by the end of the year, followed by a second white paper before the JP Morgan Healthcare Conference in January. 

Nov 09, 2020

Savran Technologies to Target Breast Cancer Recurrence with Circulating Tumor Cell Platform

Premium

The startup aims to combine its microfluidic platform with a circulating tumor DNA-based assay offered by a potential partner and launch the test by 2022.

Nov 04, 2020

Biocartis to Invest in IVD Partnerships Following Termination of Genomic Health Deal

Premium

The firm will partner with startup GeneproDx on thyroid cancer diagnostic development, while a separate agreement with Endpoint Health will entail CDx development for critical illness. 

Nov 02, 2020

Bluestar Genomics Eyes Pan-Cancer Early Detection With Epigenetic Assay Technology

Premium

Bluestar hopes to launch a pan-cancer, DNA methylation-based liquid biopsy assay as a laboratory-developed test out of an envisioned CLIA-certified lab in San Diego. 

Oct 29, 2020

Helio Heath Aims to Market Blood-Based Liver Cancer Screening Assay in Early 2021

Premium

The firm is engaged in multiple clinical validation trials and aims to raise more than $100 million to launch its Helio Liver Test in the US early next year.

The Scan

Open Spot

Politico notes that the Biden Administration has not yet nominated a permanent Food and Drug Administration commissioner. 

US to Remain in WHO

Anthony Fauci also informed the World Health Organization executive board that the US would be joining the COVAX initiative, according to CNBC.

Dip Possible

A new preprint suggests some SARS-CoV-2 variants could affect the effectiveness of current vaccines, the Associated Press reports.

Nature Papers Examine Australian Lungfish Genome, Essential E. Coli Genes

In Nature this week: Australian lungfish provides details on the movement of vertebrate life from water to land, and more.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.